<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003467</url>
  </required_header>
  <id_info>
    <org_study_id>1706</org_study_id>
    <secondary_id>DUMC-1706-02-9R5</secondary_id>
    <secondary_id>DUMC-1706-01-9R4</secondary_id>
    <secondary_id>DUMC-000693-00-4</secondary_id>
    <secondary_id>DUMC-1509-97-10</secondary_id>
    <secondary_id>DUMC-1568-98-10R1</secondary_id>
    <secondary_id>DUMC-1706-00-9R3</secondary_id>
    <secondary_id>DUMC-97131</secondary_id>
    <secondary_id>NCI-G98-1470</secondary_id>
    <secondary_id>CDR0000066503</secondary_id>
    <nct_id>NCT00003467</nct_id>
  </id_info>
  <brief_title>Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade Glioma</brief_title>
  <official_title>Phase II Treatment of Adults With Recurrent Supratentorial Low Grade Glioma With Gliadel Wafers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of carmustine in treating adults with&#xD;
      recurrent supratentorial low-grade glioma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor activity of Gliadel wafers (carmustine) in the treatment of&#xD;
           recurrent supratentorial low grade glioma.&#xD;
&#xD;
        -  Assess the toxicity of this therapy in these patients.&#xD;
&#xD;
      OUTLINE: Patients are stratified by disease (fibrillary astrocytoma vs oligodendroglioma or&#xD;
      mixed glioma).&#xD;
&#xD;
      Patients receive up to 8 Gliadel wafers (containing carmustine) implanted in the resected&#xD;
      tumor cavity.&#xD;
&#xD;
      Patients are followed every 2 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: This study will accrue a maximum of 68 patients within 18-24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1998</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>polifeprosan 20 with carmustine implant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgical procedure</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent primary low grade glioma including:&#xD;
&#xD;
               -  Fibrillary astrocytoma&#xD;
&#xD;
               -  Oligodendroglioma&#xD;
&#xD;
               -  Mixed glioma&#xD;
&#xD;
          -  Evidence of measurable enhancing or non-enhancing CNS neoplasm on MRI&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hematocrit greater than 29%&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 125,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  SGOT less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin less than 1.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 mg/dL&#xD;
&#xD;
          -  BUN less than 25 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy unless disease progression&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent corticosteroids allowed (must be on stable dose for 1 week prior to study)&#xD;
&#xD;
          -  No concurrent immunosuppressive agents&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy unless disease progression&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent medication that may interfere with study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry S. Friedman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 19, 2013</last_update_submitted>
  <last_update_submitted_qc>June 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <name_title>Henry Friedman, MD</name_title>
    <organization>Duke UMC</organization>
  </responsible_party>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>adult brain stem glioma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult pilocytic astrocytoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carmustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

